Form 4: Aprea Therapeutics Executive Acquires Shares and Stock Options

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, reports acquisition of common stock and stock options.

Summary

• On March 28, 2024, John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, acquired 3,365 shares of common stock and 13,460 stock options.
• The common stock was acquired at a price of $0.00.
• These shares represent restricted stock units (RSUs) that vest in three equal annual installments beginning on March 28, 2025.
• Twenty-five percent of the options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months.
• Following the transaction, Hamill directly owns 18,868 shares of common stock and 13,460 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard executive compensation practices. The acquisition of shares and options could be interpreted as a positive sign of confidence, but it's a routine occurrence.

Positives

• The acquisition of shares and options by a senior executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The RSUs vest in three equal annual installments beginning on March 28, 2025, and the stock options vest over time, contingent on continued employment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company executives.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a key executive.
• Employees may view the executive's stock acquisition as a positive sign for the company's future.

Next Steps

• Monitor future Form 4 filings to track changes in insider ownership.
• Track the vesting dates of the RSUs and stock options.

Key Dates